http://www.phlbi.org/wp-content/uploads/PHLBI-Logo-340_332-300x293.png 0 0 Lien http://www.phlbi.org/wp-content/uploads/PHLBI-Logo-340_332-300x293.png Lien2017-08-23 11:21:372017-09-12 23:22:45The 7th International Symposium on Mesothelioma: Meet the Speakers Part Two
L-R: Jacques P. Fontaine, MD, Arti Shukla, PhD, Brian Cunniff, PhD, and David S. Schrump, MD, MBA,FACS
The Pacific Mesothelioma Center and UCLA will host the 7th International Symposium on Malignant Pleural Mesothelioma on Saturday, September 30th at the UCLA Luskin Conference Center. Mesothelioma experts from around the world will convene to discuss the latest research and treatment options for mesothelioma. Meet some of the international speakers below. For more information on additional speakers click here
The Symposium’s Distinguished Panel Includes:
Jacques Fontaine, MD, Dr. Fontaine received his medical degree from McGill University in Montreal and completed his general surgery residency at Boston University. In 2006, he graduated as chief resident in thoracic surgery at Brigham and Women’s Hospital – Harvard Medical School. Dr. Fontaine began his thoracic surgery practice at the University of Montreal but was then recruited to become a part of the Department of Thoracic Surgery at Brown Medical School in Providence, RI. He was in charge of developing a thoracic surgery program at one of Brown University’s teaching hospitals. In 2011, Dr. Fontaine joined Moffitt Cancer Center in Tampa, FL, one of the top three largest cancer centers in the United States based on patient volume. Dr. Fontaine has a keen interest in mesothelioma, lung and esophageal cancers. He is the Section Head of the Mesothelioma Research and Treatment Center. He has developed an expertise in robotic surgery and is the Program Director for Moffitt’s Robotic Thoracic Fellowship Program.
Arti Shukla, PhD, Arti Shukla, has a MS and PhD in Biochemistry from Banaras Hindu University in India. Her present research interest lies in studying cell signaling mechanisms of asbestos fibers-induced lung diseases including lung cancer and mesothelioma. Shukla and her team are exploring asbestos-induced signaling mechanisms in human mesothelial cells as well as in different mesothelioma cell lines to be targeted by different anti-cancer drugs in combination with pathway inhibitors. The current focus of their group is to demonstrate the role of inflammation with special emphasis on inflammasomes in malignant mesothelioma pathogenesis. The goal is to reveal the role of inflammasomes in development of asbestos–induced mesothelioma and to manipulate them to develop potential therapeutic strategies for malignant mesothelioma.
Brian Cunniff, PhD, Brian Cunniff is a Faculty Scientist in the Department of Pathology at the University Of Vermont College Of Medicine. His research focuses on how changes in mitochondrial structure and function influence signaling pathways that contribute to tumor cell survival, proliferation and migration. Additionally, Dr. Cunniff has a deep interest in identifying, characterizing and targeting metabolic pathways that are universal among cancer types for the treatment of intractable tumors such as malignant mesothelioma using in vivo, biochemical and imaging tools.
David S. Schrump, MD, MBA, FACS Dr. Schrump is Senior Investigator, and Co-Chief of the Thoracic and GI Oncology Branch at the National Cancer Institute. In addition to maintaining an active thoracic surgery practice, he oversees clinical and translational research pertaining to thoracic and gastrointestinal malignancies, including the development of innovative molecular approaches to the diagnosis and treatment of these neoplasms. He has pioneered the development of epigenomic therapies for thoracic cancers. Using unique in-vitro models and correlative experiments with surgical specimens, he has characterized epigenetic responses to tobacco and other environmental carcinogens, and identified novel therapeutic targets in lung and esophageal cancers and pleural mesotheliomas that are now being evaluated in early phase clinical trials at the NCI. Dr. Schrump graduated from the University of Connecticut School of Medicine. He completed a residency in General Surgery at the University of Chicago, as well as a 3-year research fellowship in Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center. Thereafter, he completed a Thoracic Surgery residency at the University of Michigan, and was a member of the Thoracic and Cardiovascular Surgery Department at MD Anderson Cancer Center prior to his recruitment to the NCI in 1997.
If you would like attend the symposium click here to register. Registration fees before September 6th are
- Physicians :$150
- Nurses :$100
- Family & Patients:$75
- Legal Profession:$400
All physicians and nurses attending will receive continuing medical education (CME) course credit. Patients and families are welcome and encouraged to attend.
Breakfast, lunch and coffee included in registration fee.